Using the optimal method-explained variance weighted genetic risk score to predict the efficacy of folic acid therapy to hyperhomocysteinemia.

Chen, Xiaorui; Huang, Xiaowen; Zheng, Caifang; Wang, Xiliang; Zhang, Weidong

Chen, Xiaorui; Huang, Xiaowen; Zheng, Caifang; Wang, Xiliang; Zhang, Weidong.

Afiliação

Chen X; Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
Huang X; Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
Zheng C; Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
Wang X; Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
Zhang W; Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, Henan, China. imooni@163.com.

Eur J Clin Nutr ; 76(7): 943-949, 2022 07.

Article em En | MEDLINE | ID: mdl-35001080

Assuntos

Hiper-Homocisteinemia; Ácido Fólico/uso terapêutico; Predisposição Genética para Doença; Humanos; Hiper-Homocisteinemia/tratamento farmacológico; Hiper-Homocisteinemia/genética; Polimorfismo de Nucleotídeo Único; Estudos Prospectivos; Fatores de Risco

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hiper-Homocisteinemia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Clin Nutr Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google